Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 499 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Positive Choice Clear all
Terminated Phase 1Phase 2 Interventional Results available

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

NCT01823835
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-0810, LHRH Agonist, Palbociclib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
8
States / cities
San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 30, 2026, 6:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

eMOTION: Examining Implicit Attitudes in Physical Activity Engagement

NCT07044570
View directory record Official record
Conditions
Physical Activity, Overweight or Obesity, Cancer
Interventions
Physical Activity Goals mHealth Intervention, TYPE/CONTEXT enhancement, SAVOR enhancement
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 1Phase 2 Interventional

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2

NCT03466320
View directory record Official record
Conditions
AML, MDS
Interventions
NKR-2
Biological
Lead sponsor
Celyad Oncology SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus

NCT01353027
View directory record Official record
Conditions
Ebola Hemorrhagic Fever
Interventions
Placebo, AVI-6002
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Not applicable Interventional

Increasing Help-Seeking in Military Service Members

NCT04043936
View directory record Official record
Conditions
Military Service Members at Elevated Suicide Risk
Interventions
Cognitive Bias Modification Intervention for Help-Seeking Stigma, Placebo Cognitive Bias Modification (CBM-Placebo), Self-Directed Psychoeducation
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Tallahassee, Florida • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 30, 2026, 6:10 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Improving Social, Emotional, Behavioral, and Academic Functioning

NCT05425381
View directory record Official record
Conditions
Depression, Anxiety, Disruptive Behavior Disorder, Trauma, Psychological
Interventions
Enhanced version of Interconnected Systems Framework, Positive Behavioral Interventions and Supports with Co-located School Mental Health
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
Not listed
Enrollment
1,208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
2
States / cities
Greenville, North Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 2 Interventional

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

NCT06433219
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Tuvusertib (M1774), Niraparib, Lartesertib (M4076)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Digital Narrative Bibliotherapy as a Scalable Intervention for Suicidal Thoughts

NCT05351645
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Treatment
Behavioral
Lead sponsor
Harvard University
Other
Eligibility
18 Years and older
Enrollment
864 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 3 Interventional Results available

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

NCT03901339
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
55
States / cities
Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 30, 2026, 6:10 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

NCT05849298
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
AAA617, AAA517, Piflufolastat F 18, ARPI, ADT, Best supportive care
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Denver, Colorado • Athens, Georgia • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

NCT03674112
View directory record Official record
Conditions
HER2-Positive Early Breast Cancer
Interventions
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC), Pertuzumab IV, Trastuzumab IV
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Lakewood, Colorado • Peoria, Illinois • Wichita, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

NCT01154140
View directory record Official record
Conditions
Non Squamous Lung Cancer
Interventions
treatment
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
84
States / cities
Beverly Hills, California • Fontana, California • Loma Linda, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

NCT03615326
View directory record Official record
Conditions
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions
Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Monterey, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Weight Discrimination and Poor Cardiovascular Health

NCT05714696
View directory record Official record
Conditions
Obesity
Interventions
Weight discrimination experience, Control experience
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 30, 2026, 6:10 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Network-Based Support to Help Community Coalition Members Choose and Use Strategies to Improve Child Health

NCT07804550
View directory record Official record
Conditions
Childhood Obesity, Evidence-Based Practice, Food Systems, Food Policy
Interventions
Catalyzing Communities, FICAS Implementation Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
3,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Completed No phase listed Observational

A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

NCT03955913
View directory record Official record
Conditions
Urothelial Cancer, Receptors, Fibroblast Growth Factor
Interventions
Archival Tumor Tissue Sample
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
3,679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 30, 2026, 6:10 AM EDT
Recruiting Not applicable Interventional

Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching

NCT05662462
View directory record Official record
Conditions
Pre-Gestational Diabetes, Type2diabetes, Pregnancy in Diabetic, Pregnancy, High Risk
Interventions
DEXCOM G7 PRO Continuous Glucose Monitor, Patient mHealth app linked to a provider dashboard, Care team coaching for medical and social needs (HUB), Provider dashboard
Device · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Results available

Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer

NCT02784288
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Cancer
Interventions
Neck Dissection, Standard-of-Care (SOC) Transoral Surgery of Primary Site, SOC Radiation, SOC Carboplatin, SOC Paclitaxel, Videofluoroscopy
Procedure · Radiation · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 30, 2026, 6:10 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

NCT07762703
View directory record Official record
Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin
Drug
Lead sponsor
BreakBio Corp
Industry
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Not listed Phase 1Phase 2 Interventional

The Effects of Summer Employment on Disadvantaged Youth: Experimental Evidence

NCT01947452
View directory record Official record
Conditions
Reduce Violence and Crime, Increase School Engagement, Increase Future Labor Market Outcomes
Interventions
Employment, Social-Emotional Learning
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
14 Years to 21 Years
Enrollment
1,634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Phase 1 Interventional

F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies

NCT03456908
View directory record Official record
Conditions
Myeloma Before MV-NIS Treatment, Endometrial Cancer Before VSV-hINF-NIS Treatment
Interventions
18F-TFB-PET
Combination Product
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 30, 2026, 6:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

NCT04939610
View directory record Official record
Conditions
Solid Tumor
Interventions
68Ga-FAP-2286, 177Lu-FAP-2286
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 30, 2026, 6:10 AM EDT
Completed Not applicable Interventional Results available

Motivational Interviews for Depression in Primary Care

NCT01114334
View directory record Official record
Conditions
Major Depression
Interventions
Guideline-Based Medical Management, Motivational Interviewing for Depression
Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 30, 2026, 6:10 AM EDT
Recruiting Not applicable Interventional

Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit

NCT07173205
View directory record Official record
Conditions
Depression, Cancer, Adolescent, Young Adult, Adult
Interventions
AYA Survivors Coping and Emotional Needs Toolkit (ASCENT)
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
15 Years to 39 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Greenville, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 30, 2026, 6:10 AM EDT